Sanuwave Health (NASDAQ:SNWV) Rating Lowered to "Strong Sell" at Zacks Research

Key Points

• Zacks Research downgraded Sanuwave Health from a "Hold" to a "Strong Sell" in a note issued Monday, signaling a negative view from that major research firm.
• Analyst opinions are mixed—ranging from Strong Buy to Sell—with a MarketBeat consensus of "Moderate Buy" and a notable consensus target of $51, far above the current share price.
• Sanuwave recently missed quarterly EPS and revenue expectations (EPS $0.03 vs. $0.17 expected; revenue $13.09M vs. $13.23M), trades around $17.29 with a market cap of ~$148.5M, and shows a negative return on equity and negative P/E.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) was downgraded by research analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued on Monday,Zacks.com reports.

A number of other research firms have also recently weighed in on SNWV. Roth Mkm restated a "buy" rating and issued a $47.00 price target (down from $53.00) on shares of Sanuwave Health in a report on Monday. Weiss Ratings raised Sanuwave Health from a "sell (d-)" rating to a "hold (c-)" rating in a report on Friday. Finally, Wall Street Zen downgraded Sanuwave Health from a "buy" rating to a "hold" rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $51.00.

Sanuwave Health Stock Down 0.6%

SNWV stock opened at $17.29 on Monday. The company has a current ratio of 1.38, a quick ratio of 1.05 and a debt-to-equity ratio of 10.08. The company's 50-day moving average price is $23.63 and its 200 day moving average price is $29.06. Sanuwave Health has a 52 week low of $16.27 and a 52 week high of $46.58. The company has a market cap of $148.52 million, a P/E ratio of -108.06 and a beta of 1.32.

Sanuwave Health (NASDAQ:SNWV - Get Free Report) last issued its earnings results on Thursday, March 26th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by ($0.14). Sanuwave Health had a net margin of 26.64% and a negative return on equity of 141.56%. The company had revenue of $13.09 million during the quarter, compared to analysts' expectations of $13.23 million.

Institutional Trading of Sanuwave Health

Several large investors have recently modified their holdings of the business. Corient Private Wealth LLC acquired a new position in shares of Sanuwave Health during the 4th quarter worth approximately $257,000. Praetorian PR LLC lifted its stake in Sanuwave Health by 1,436.2% in the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company's stock valued at $7,908,000 after buying an additional 247,750 shares in the last quarter. Bridgeway Capital Management LLC grew its holdings in Sanuwave Health by 76.3% during the 4th quarter. Bridgeway Capital Management LLC now owns 39,279 shares of the company's stock valued at $1,172,000 after buying an additional 17,000 shares during the last quarter. Barclays PLC grew its holdings in Sanuwave Health by 12.7% during the 4th quarter. Barclays PLC now owns 11,610 shares of the company's stock valued at $346,000 after buying an additional 1,306 shares during the last quarter. Finally, Stifel Financial Corp purchased a new position in Sanuwave Health during the fourth quarter worth $5,291,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company's proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body's natural repair mechanisms. Sanuwave's primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company's lead product, the dermaPACE® system, holds clearance from the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.